Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:GLUE NASDAQ:SLS NASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$12.53$10.22$2.25▼$14.76$1.69B2.53.40 million shs3.62 million shsGLUEMonte Rosa Therapeutics$18.31$18.65$4.12▼$25.77$1.55B1.61.03 million shs2.51 million shsSLSSELLAS Life Sciences Group$8.05$6.64$1.39▼$9.51$1.58B2.58.23 million shs14.72 million shsYMABY-mAbs Therapeutics$8.61$8.58$3.55▼$8.61$391.24M0.54637,200 shsN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways0.00%+3.73%+8.11%+131.61%+161.04%GLUEMonte Rosa Therapeutics0.00%+0.38%-3.02%+17.15%+307.80%SLSSELLAS Life Sciences Group0.00%+2.81%+6.48%+69.12%+412.74%YMABY-mAbs Therapeutics0.00%0.00%0.00%0.00%+85.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$12.53$10.22$2.25▼$14.76$1.69B2.53.40 million shs3.62 million shsGLUEMonte Rosa Therapeutics$18.31$18.65$4.12▼$25.77$1.55B1.61.03 million shs2.51 million shsSLSSELLAS Life Sciences Group$8.05$6.64$1.39▼$9.51$1.58B2.58.23 million shs14.72 million shsYMABY-mAbs Therapeutics$8.61$8.58$3.55▼$8.61$391.24M0.54637,200 shsN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways0.00%+3.73%+8.11%+131.61%+161.04%GLUEMonte Rosa Therapeutics0.00%+0.38%-3.02%+17.15%+307.80%SLSSELLAS Life Sciences Group0.00%+2.81%+6.48%+69.12%+412.74%YMABY-mAbs Therapeutics0.00%0.00%0.00%0.00%+85.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCompass Pathways 2.93Moderate Buy$21.3670.50% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$32.5077.50% UpsideSLSSELLAS Life Sciences Group 2.00Hold$10.0024.22% UpsideYMABY-mAbs Therapeutics 2.00Hold$8.60-0.12% DownsideCurrent Analyst Ratings BreakdownLatest YMAB, CMPS, SLS, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026CMPSCompass Pathways TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026CMPSCompass Pathways Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/15/2026CMPSCompass Pathways Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $20.005/14/2026CMPSCompass Pathways Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $17.005/14/2026CMPSCompass Pathways Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $22.005/13/2026CMPSCompass Pathways BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.005/11/2026GLUEMonte Rosa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/11/2026GLUEMonte Rosa Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $31.005/7/2026CMPSCompass Pathways UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$18.00(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCompass PathwaysN/AN/AN/AN/A($0.55) per shareN/AGLUEMonte Rosa Therapeutics$123.67M12.51N/AN/A$3.58 per share5.11SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/AYMABY-mAbs Therapeutics$87.68M4.46N/AN/A$2.05 per share4.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)GLUEMonte Rosa Therapeutics-$38.63M-$1.48N/AN/AN/A-302.69%-40.99%-25.94%8/6/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%N/ALatest YMAB, CMPS, SLS, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/A5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3882-$0.45-$0.0618-$0.45$10.95 million$4.21 million3/24/2026Q4 2025CMPSCompass Pathways-$0.41-$1.00-$0.59-$1.00N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCompass PathwaysN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCompass Pathways0.153.323.32GLUEMonte Rosa TherapeuticsN/A9.549.54SLSSELLAS Life Sciences GroupN/A17.2217.22YMABY-mAbs TherapeuticsN/A4.003.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCompass Pathways46.19%GLUEMonte Rosa Therapeutics79.96%SLSSELLAS Life Sciences Group17.38%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipCMPSCompass Pathways2.82%GLUEMonte Rosa Therapeutics6.40%SLSSELLAS Life Sciences Group1.30%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableGLUEMonte Rosa Therapeutics9084.48 million79.07 millionOptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableYMABY-mAbs Therapeutics15045.44 million36.49 millionOptionableYMAB, CMPS, SLS, and GLUE HeadlinesRecent News About These CompaniesY-Mabs Therapeutics Completes Merger with Perseus BidCoSeptember 16, 2025 | tipranks.comY-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma TreatmentSeptember 7, 2025 | msn.comY-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?September 1, 2025 | zacks.comY-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 19, 2025 | globenewswire.comAcquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics StockAugust 13, 2025 | insidermonkey.comA Look Ahead: Y-mAbs Therapeutics's Earnings ForecastAugust 9, 2025 | benzinga.comY-mAbs (YMAB) Q2 Revenue Falls 14%August 9, 2025 | aol.comAY-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2025 | zacks.comShareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersAugust 8, 2025 | businesswire.comY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 8, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)August 7, 2025 | prnewswire.comY-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 7, 2025 | businesswire.comY-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings CallAugust 7, 2025 | quiverquant.comQY-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025August 7, 2025 | globenewswire.comHC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)August 7, 2025 | msn.comSERB bets on rare cancer drug in $412 million deal for Y-mAbsAugust 6, 2025 | thepharmaletter.comTJones Trading Downgrades Y-mAbs Therapeutics (YMAB)August 6, 2025 | msn.comYmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?August 6, 2025 | zacks.comShareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersAugust 5, 2025 | prnewswire.comY-mAbs stock soars after SERB Pharmaceuticals announces acquisitionAugust 5, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYMAB, CMPS, SLS, and GLUE Company DescriptionsCompass Pathways NASDAQ:CMPS$12.53 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$12.46 -0.06 (-0.52%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Monte Rosa Therapeutics NASDAQ:GLUE$18.31 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$18.33 +0.02 (+0.11%) As of 06/18/2026 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.SELLAS Life Sciences Group NASDAQ:SLS$8.05 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$8.14 +0.09 (+1.18%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Y-mAbs Therapeutics NASDAQ:YMABY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
